NHS Patient Information Summary – Tirzepatide (Mounjaro®) for Managing Obesity

Official NHS patient guidance on tirzepatide (Mounjaro®) for managing obesity in adults in primary care outlines the key clinical messaging, long-term treatment principles, mandatory wraparound support, and patient expectations when prescribed weight loss medication (1):

Key Clinical and Patient Management Principles

Eligibility and NHS Prioritisation

• targeted prescribing: NHS provision prioritises individuals who need treatment most, specifically adults living with obesity whose weight impacts their health or who have weight-related co-morbidities
• clinical oversight: can be prescribed in primary care by GPs for patients who meet national guidelines

Efficacy and Treatment Duration

• weight loss expectations: individual responses vary, but clinical trials demonstrate up to 15% to 20% total body weight loss within the first 6 months
• long-term therapy: tirzepatide is designed as a long-term treatment that only works while maintained; stopping the medication increases appetite and leads to weight regain
• lifestyle integration: sustainable lifestyle changes (eating habits and physical activity) during treatment are essential for long-term weight maintenance

Clinical Review and Healthcare Monitoring

• routine appointments: patients undergo regular clinical check-ups with a GP, nurse, or pharmacist
• clinical review scope:
  • monitoring, managing, and reviewing side effects
  • reviewing weight loss progress and general health conditions
  • evaluating concomitant medications alongside weight loss therapy

Mandatory NHS Behavioural Support Programme

• wraparound requirement: prescribing must be accompanied by comprehensive wraparound support combining clinical monitoring and behavioral change interventions
• 9-month programme: patients are enrolled in the free 9-month NHS Behavioural Support for Obesity Prescribing Programme
• delivery formats: delivered over 9 months via 13 group sessions (in person or via video call) or online with check-ins every few weeks
• core content: provides tailored guidance on nutrition/building healthy habits, maintaining physical activity to preserve muscle and bone strength, and managing stress, cravings, and setbacks
• prescribing dependency: engagement with the behavioural support programme is mandatory for safe use; failure to participate may result in discontinuation of tirzepatide prescribing

Patient Resource Link

• NHS Patient Information Leaflet: Tirzepatide (Mounjaro®) for Managing Obesity

Reference:

1. NHS England (October 20th 2026). Tirzepatide (Mounjaro®) for managing obesity – patient leaflet.